Detailed review of mortality reported following COVID-19 vaccination in Victoria, Australia: 2021-2023.

Autor: Laemmle-Ruff I; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of General Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia. Electronic address: ingrid.laemmleruff@mcri.edu.au., Fryk JJ; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Centre for Health Analytics, Royal Children's Hospital, Melbourne, Victoria, Australia., Shenton P; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of General Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia., Clothier HJ; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Centre for Health Analytics, Royal Children's Hospital, Melbourne, Victoria, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia; School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia., Parsons S; Victorian Institute of Forensic Medicine, Melbourne, Victoria, Australia; Department of Forensic Medicine, Monash University, Victoria, Australia., Iles L; Victorian Institute of Forensic Medicine, Melbourne, Victoria, Australia., White C; Department of Geriatric Medicine, Western Health, Melbourne, Victoria, Australia., Murray M; Department of Geriatric Medicine, Austin Health, Melbourne, Victoria, Australia., Buttery J; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Centre for Health Analytics, Royal Children's Hospital, Melbourne, Victoria, Australia; Department of General Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia., Crawford NW; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of General Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Dec 02; Vol. 42 (26), pp. 126368. Date of Electronic Publication: 2024 Sep 20.
DOI: 10.1016/j.vaccine.2024.126368
Abstrakt: Introduction: The scale of the COVID-19 vaccine program, and appropriate focus on older individuals, emphasised monitoring of mortality as an important part of COVID-19 vaccine safety surveillance, noting many deaths temporally associated with vaccination may not be causally related. This cross-sectional study describes Victoria's vaccine safety service (SAEFVIC) process of reviewing mortality reports following COVID-19 vaccination, summarises report characteristics and identifies trends in mortality reporting.
Methods: Mortality cases reported to SAEFVIC following COVID-19 vaccination from 22 February 2021 to 22 February 2023 were included. Report characteristics, demographics, and cause of death information were described. Proportions of mortality reports per 100,000 vaccine doses administered were calculated, overall and stratified by age (<60 years, ≥60 years), sex, vaccine type and dose number. Rate ratios (RR) were used to compare proportions.
Results: Reporting proportions were higher in the first three months of the vaccine program (3.98 per 100,000 doses), compared to the following 21 months (0.71 per 100,000 doses), RR:5.61, p < 0.001. Of 159 mortality reports included, 135/159 (84.9 %) were in individuals ≥60 years. Most individuals (121/159, 90.3 %) had comorbidities relevant to cause(s) of death, and 143/159 (89.9 %) were categorised as having a 'likely alternate' cause of death based on treating clinician/forensic assessment. For 11/159 (6.9 %) reports vaccine contribution to death could not be determined. Five deaths (0.03 per 100,000 doses administered), all publicly reported, were assessed by the national regulator as likely vaccine-associated.
Conclusions: Mortality reporting predominantly reflected the health status of the population receiving vaccines, vaccine administration patterns and contextual factors surrounding COVID-19 vaccines (including public concerns regarding serious adverse events of special interest), as well as extremely rare but fatal adverse events that were likely vaccine-associated. Jurisdictional vaccine safety services such as SAEFVIC play an important role in follow-up of mortality reports, supporting the work of national regulators, and thereby supporting vaccine safety surveillance and vaccine confidence more broadly.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jim Buttery is a site investigator for non-COVID vaccine related clinical trials for both Pfizer and AstraZeneca. He does not receive compensation for this but his (former) employer Monash Health is compensated for his time. All other authors have no relevant financial or other conflicts of interest pertaining to this submission.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: